TÍNH AN TOÀN VÀ TÁC DỤNG PHỤ CỦA THUỐC NHỎ MẮT CHỨA ATROPINE 0,05% TRONG KIỂM SOÁT TIẾN TRIỂN CẬN THỊ: NGHIÊN CỨU CẮT DỌC THEO DÕI 1 NĂM

Abstract

Objective: Our longitudinal assessment of 0.05% atropine evaluated its safety and side effects after one year to provide evidence for clinical application in pediatric myopia management. Subjects and Methods: A randomized, single-blind, placebo-controlled clinical trial conducted on 53 children (106 eyes) aged 7-12 years, randomly divided into two groups: a group using 0.05% atropine and a control group using 0.9% NaCl. The outcomes included best corrected distance visual acuity, near visual acuity, accommodation amplitude, pupil size, and intraocular pressure. Results: Best corrected distance visual acuity remained excellent (approximately 0.00 LogMAR) in all groups with no significant difference between groups (p > 0.05). Accommodation amplitude decreased from 13.16 D to 9.46 D in the atropine group but did not significantly affect near visual acuity. Pupil size increased slightly, from 6.29 ± 0.83 mm to 6.81 ± 0.93 mm. Intraocular pressure remained stable and within normal limits in both groups over the visits. Conclusions: 0.05% atropine appeared to be a safe method with minimal side effects for controlling myopia progression in children with no significant effect on best corrected distance visual acuity, near visual acuity, or intraocular pressure in children, although accommodation amplitude and pupil size showed statistically significant changes.